ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Innovative Industrial Properties, Inc. Investors to Secure Counsel Before Important Deadline in First Filed Securities Class Action Initiated by the Firm – IIPR, IIPR-PA

NEW YORK, May 23, 2022 (GLOBE NEWSWIRE) — WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Innovative Industrial Properties, Inc. (NYSE: IIPR, IIPR-PA) between May 7, 2020 and April 13, 2022, inclusive (the “Class Period”), of the important June 24, 2022 lead plaintiff deadline in the securities class action commenced by the Firm.

SO WHAT: If you purchased Innovative Industrial Properties securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the Innovative Industrial Properties class action, go to https://rosenlegal.com/submit-form/?case_id=5301 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than June 24, 2022. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources or any meaningful peer recognition. Many of these firms do not actually handle securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose: (1) that Innovative Industrial Properties’ focus is to be a cannabis company lender rather than a real estate investment trust (REIT); (2) that the true values of Innovative Industrial Properties’ properties are significantly lower than Innovative Industrial Properties represents; (3) existential issues in its top customers; (4) that as a result, its top customers may not be able to continue making payments to Innovative Industrial Properties and Innovative Industrial Properties would face significant issues replacing these customers; and (5) that as a result, defendants’ statements about its business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Innovative Industrial Properties class action, go to https://rosenlegal.com/submit-form/?case_id=5301 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

——————————

Contact Information:

Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
lrosen@rosenlegal.com
pkim@rosenlegal.com
cases@rosenlegal.com
www.rosenlegal.com

ROSEN, GLOBAL INVESTOR COUNSEL, Encourages International Business Machines Corporation Investors to Secure Counsel Before Important June 6 Deadline in Securities Class Action – IBM

NEW YORK, May 23, 2022 (GLOBE NEWSWIRE) —

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of International Business Machines Corporation (NYSE: IBM) between April 4, 2017 and October 20, 2021, inclusive (the “Class Period”), of the important June 6, 2022 lead plaintiff deadline.

SO WHAT: If you purchased IBM securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the IBM class action, go to https://rosenlegal.com/submit-form/?case_id=5104 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than June 6, 2022. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually handle securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) Strategic Imperatives Revenue and growth, CAMSS (the sectors of “Cloud,” “Analytics,” “Mobile,” “Security,” and “Social”) and CAMSS Components’ revenue and growth, and the Company’s Segments’ revenue and growth were artificially inflated as a result of the wrongful reclassification of revenues from non-strategic to strategic to make those revenues eligible for treatment as Strategic Imperatives Revenue; (2) IBM’s present success and positive future growth prospects concerning its Strategic Imperative business strategy were being fueled by the wrongful reclassification of revenues from non-strategic to strategic to make those revenues eligible for treatment as Strategic Imperative Revenue; (3) as a result of the foregoing, defendants misled the market by portraying IBM’s Strategic Imperative’s financial performance and future prospects more favorable than they actually were as a result of the fraudulent scheme and/or the wrongful reclassification of revenues from non-strategic to strategic to make those revenues eligible for treatment as Strategic Imperatives; and (4) Total Revenue and IBM’s Segments’ revenue and growth were artificially inflated as a result of the fraudulent scheme and/or the wrongful reclassification of revenues from non-strategic to strategic and/or the wrongful recognition of revenue. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the IBM class action, go to https://rosenlegal.com/submit-form/?case_id=5104 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

——————————

Contact Information:

Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
lrosen@rosenlegal.com
pkim@rosenlegal.com
cases@rosenlegal.com
www.rosenlegal.com

ROSEN, GLOBAL INVESTOR COUNSEL, Encourages First High-School Education Group Co., Ltd. Investors to Secure Counsel Before Important Deadline in Securities Class Action – FHS

NEW YORK, May 23, 2022 (GLOBE NEWSWIRE) —

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of First High-School Education Group Co., Ltd. (NYSE: FHS) pursuant and/or traceable to the registration statement and prospectus (collectively, the “Registration Statement”) issued in connection with the Company’s March 2021 initial public offering (“IPO” or the “Offering”) of the important July 11, 2022 lead plaintiff deadline.

SO WHAT: If you purchased First High-School Education Group securities pursuant and/or traceable to the Registration Statement you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the First High-School Education Group class action, go to https://rosenlegal.com/submit-form/?case_id=6131 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than July 11, 2022. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources or any meaningful peer recognition. Many of these firms do not actually handle securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, the IPO Registration Statement was materially false and misleading and omitted to state: (1) the new rules, regulations, and policies to be implemented by the Chinese government following the Two Sessions parliamentary meetings were far more severe than represented to investors and posed a material adverse threat to First High-School Education Group and its business; (2) contemplated Chinese regulations and rules regarding private education were leading to a slowdown of government approval to open new educational facilities which would have a negative effect on First High-School Education Group’s enrollment and growth; and (3) as a result, the Registration Statement’s representations regarding First High-School Education Group’s historical financial and operational metrics and purported market opportunities did not accurately reflect the actual business, operations, and financial results and trajectory of First High-School Education Group at the time of the IPO, and were materially false and misleading and lacked a factual basis. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the First High-School Education Group class action, go to https://rosenlegal.com/submit-form/?case_id=6131 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

——————————

Contact Information:

Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
lrosen@rosenlegal.com
pkim@rosenlegal.com
cases@rosenlegal.com
www.rosenlegal.com

Hitachi launches Lumada Inspection Insights and strengthens digital and green portfolio

Committed to driving customer value and growth by combining world-class IT and OT expertise from Hitachi Energy and Hitachi Vantara within expanded Lumada portfolio

Zurich, Switzerland, May 23, 2022 (GLOBE NEWSWIRE) — Hitachi, Ltd. (TSE:6501) today announced the launch of Lumada Inspection Insights, its end-to-end portfolio of digital solutions for the inspection, monitoring, and optimization of critical assets. Pioneered by Hitachi Energy and Hitachi Vantara, Lumada Inspection Insights enables customers to automate asset inspection, support sustainability goals, improve physical security, and reduce risks and impacts related to storms or fires by using powerful artificial intelligence (AI) to analyze photographs and video, including LiDAR, thermal and satellite imagery.

The launch of the new portfolio is fully aligned with Hitachi’s Mid-term Management Plan 2024 announced last month by Keiji Kojima, President & CEO, Hitachi, Ltd. In the Plan, Hitachi has set out its growth strategy and commitment to strengthening its digital and green portfolio, which is centered on the Lumada ecosystem. Central to Hitachi’s commitment to social innovation, the Lumada ecosystem is accelerating the journey towards sustainable society through the data-driven cycle of value co-creation with customers. The company is also focused on growing its IT/OT/Products business through constant portfolio transformation.

The new Lumada Inspection Insights portfolio addresses various root causes of failures and forced shutdowns by deploying AI and machine learning (ML) to analyze a wide spectrum of image types, assets and risks. Predictive analytics assesses the risks to operations or environment, and organizations can streamline remediation before outages occur. Available as a comprehensive solution or standalone, the portfolio’s four core applications are Hitachi Image Based Inspections, Hitachi Intelligent Infrastructure Monitoring, Hitachi Vegetation Manager, and Hitachi Map. These represent the company’s latest advancements in its growing Data Operations (DataOps) and Industrial IoT offerings. More information on each solution is below.

Massimo Danieli, Managing Director of Hitachi Energy’s Grid Automation business, said, “The energy transition is one of the most urgent issues of our times and together with customers, we are co-creating pioneering digital solutions to enable the carbon-neutral future.” He added, “In collaboration with Hitachi Vantara, we are delighted to launch the Lumada Inspection Insights portfolio, which gives industrial organizations the tools they need to get the right information to the right teams when they need it most. The result is improved reliability, safety, and sustainability.”

Frank Antonysamy, Chief Digital Solutions Officer, Hitachi Vantara, said, “Becoming data driven is essential to accelerating digitalization and sustainability. This collaboration across Hitachi creates better outcomes for businesses, broader society and our environment by harnessing data and AI to solve multiple operational and business challenges. Together, we can improve industrial asset reliability, prevent wildfires and accelerate global sustainability efforts.”

Lumada Inspection Insights features comprehensive, microservices-based capabilities that allow visibility of assets and factors such as current state, asset health, and encroachment, in a “single pane of glass” actionable view, from a variety of sources. With these unified insights, organizations can improve safety, reliability, and agility. The use of high-resolution, autonomous, and accurate wide-area surveillance ensures that truck rolls and workforce deployments are optimized, reducing waste and furthering a sustainable approach to operations and maintenance.

Utilities around the world are dealing with unprecedented climate-related challenges. In 2021, global wildfires generated an estimated total of 6,450 megatons of COequivalent – approximately 148 percent more than the EU’s total fossil fuel emissions in 2020.*(1) These wildfires and other extreme weather events also take a significant toll on transmission lines and other utility assets, threatening worker safety and grid reliability.

*(1) Source: https://atmosphere.copernicus.eu/wildfires-wreaked-havoc-2021-cams-tracked-their-impact

“Inspection, planning and monitoring are among the most critical tasks utilities undertake to maintain grid reliability and resiliency,” said John Villali, Research Director, IDC Energy Insights. He added, “Lumada Inspection Insights combines a variety of visual asset data types with advanced analytics and AI. This empowers utilities to improve decision making, optimize operations and as a result, achieve their reliability, safety, and sustainability goals.”

Hitachi is exhibiting Lumada Inspection Insights at DISTRIBUTECH INTERNATIONAL 2022, which is held from May 23 at Dallas, Texas, United States.

Editor’s Notes

About the four main solutions comprising Lumada Inspection Insights

1. Hitachi Image Based Inspections (HIBI):

Conventional asset inspection methods, such as climbing tall towers or hanging from helicopters, put technicians at risk. Hitachi Image Based Inspections replaces these dangerous, expensive, and time-consuming approaches by leveraging the industry’s most sophisticated AI and machine learning (ML) capabilities in one fully automated and integrated platform. This solution provides scalable image inferencing and processing to help asset managers classify assets, detect defects and categorize defect severity. It automates defect assessment, instantly preprocessing and analyzing thousands of images. The solution’s highly optimized human-in-the-loop capabilities enable continuous retraining of model-based subject matter expert input for a wide range of asset classes and image quality.

2. Hitachi Intelligent Infrastructure Monitoring:

Utilities and other asset intensive organizations are challenged with the need to ensure that their service territories are safe and the service they provide is reliable. To meet this goal, utilities need to have insights to prevent safety incidents, or respond effectively when they happen. Hitachi Intelligent Infrastructure Monitoring leverages video, a powerful data type that is generally utilized to a fraction of its potential. With it, organizations can gather new data though smart cameras, 3D LiDAR sensors and edge gateways, and integrate with CRM, ERP, and other sources of data as required. Operators can gain granular, continuous 3D intelligence for sensitive areas (such as substations), find correlations, causations and real-time incidents.

3. Hitachi Vegetation Manager:

Hitachi Vegetation Manager is the first of its kind, closed-loop vegetation resource planning solution that leverages artificial intelligence and advanced analytics to improve the accuracy and effectiveness of an organization’s vegetation job activities and planning efforts.

The solution utilizes images from a variety of visual sources, including photo, video, and imagery from industry-leading Maxar satellites. The incorporation of satellite technology allows utilities to cover and survey their entire territory to automatically confirm line clearances and maintain compliance with regulations. Satellite technology also provides organizations with more comprehensive insights at scale, allowing them to reduce cost and emissions by minimizing truck and helicopter trips. By combining the images with climate, ecosystem and cut plan data and machine learning algorithms, Hitachi Vegetation Manager enables instant grid-wide visibility and better insights so that organizations can optimize decision-making.

4. Hitachi Map:

Hitachi Map is designed to be the primary interaction point for users, from field technicians looking for work orders in a specific area to a control center team managing a city-wide outage. It’s a “single pane of glass” from which users can access essential information, make informed decisions, and take immediate action.​ Hitachi Map combines information from numerous applications such as EAM, APM, FSM, ADMS, GIS, and more into a single, interactive and easy-to-use geospatial view. Users have intuitive access to key information at their fingertips without having to navigate multiple systems, interpret contextual variations. This approach eliminates extra and duplicative work and reduces carbon emissions from unnecessary travel to and from a site.

Attachment

Rebecca Bleasdale
Hitachi Energy Ltd.
+41 78643 2613
rebecca.bleasdale@hitachienergy.com

Late-breaking Results Show Efficacy for CCM in Patients With HFpEF

Investigators Report Positive Findings From Feasibility Study of CCM in Heart Failure With Preserved Ejection Fraction at the European Society of Cardiology Heart Failure 2022 Congress

MADRID and MARLTON, N.J., May 23, 2022 (GLOBE NEWSWIRE) — Impulse Dynamics, a global medical device company dedicated to improving the lives of people with heart failure (HF), announced today a late-breaking presentation of results from the CCM-HFpEF Piloty Study, which is the largest clinical trial to date studying the effects of the company’s proprietary CCM® therapy to treat HF with preserved ejection fraction (HFpEF). The results presented — including a substantial 18 point improvement in the Kansas City Cardiomyopathy Questionnaire (KCCQ) quality of life score — indicate that, for patients with heart failure and left ventricular ejection fraction (LVEF) ≥50%, CCM therapy not only offered meaningful improvement in quality of life but also substantially decreased hospitalizations versus the patient’s experience prior to the Optimizer® implant. The results were presented at the European Society of Cardiology’s Heart Failure 2022 Congress.

Patients with HFpEF suffer from debilitating symptoms and have very few therapeutic options. This patient population is a similar size as the one with reduced ejection fraction and has been shown to have similar struggles with quality of life, hospitalizations, and mortality.

Cecilia Linde, MD, Professor and Consultant in Cardiology at the Heart and Vascular Theme of Karolinska University Hospital and the Karolinska Institute in Stockholm, Sweden, who was the co-principal investigator for this investigation, said, “The CCM-HFpEF Pilot Study was conducted to explore the hypothesis that CCM therapy might benefit patients with HFpEF. Our hypothesis was based on evidence of greater benefits in CCM HFrEF studies in those with higher LVEF range and from case reports of HFpEF patients. In our CCM-HFpEF-Pilot Study, we found significant benefits from CCM therapy in patients with preserved LVEF, supporting prior findings. I look forward to following the progress of the recently begun pivotal AIM HIGHer trial to continue this journey further.”

Dr. Ishu Rao, Medical Director for Impulse Dynamics, welcomed these results because they confirm the potential for positive results in the company’s recently initiated AIM HIGHer trial. “We are also excited to announce that enrollment is well underway for this landmark IDE-approved, multicenter, randomized, and blinded pivotal trial designed not only to confirm Dr. Linde’s groundbreaking work presented today but to go further yet by providing the first long term morbidity and mortality results for a modern Optimizer CCM device. While Dr. Linde specifically studied patients with EFs ≥50%, in AIM HIGHer, we are examining the efficacy of CCM therapy in 1,500 patients with EFs between 40% and 60%. This represents a large cohort of patients who currently have minimal treatment options and are clamoring for help. If AIM HIGHer’s results are consistent with Dr. Linde’s findings, we may finally begin to close the significant gap in care that exists for millions of patients afflicted with HF and higher EF.”

HF affects more than 64 million people worldwide and leads to dramatic declines in a patient’s quality of life. Patients are often classified by a measure of cardiac function known as the ejection fraction (EF), which describes the percentage of blood pumped out of the left ventricle with each heartbeat. CCM therapy is currently indicated in Europe for patients that have an EF below 50% and has been proven to reduce hospitalizations. However, HF patients with higher EF have had few therapeutic options thus far to alleviate their symptoms and treat their disease.

The purpose of the AIM HIGHer trial — the largest randomized, sham-controlled, device-based interventional heart failure trial — is to further assess the potential of CCM to improve performance and reduce cardiovascular morbidity and mortality for these patients. CCM therapy for HFpEF has already received the FDA’s breakthrough device designation. The Breakthrough Devices Program is a voluntary program for certain medical devices that provide more effective treatment or diagnosis of life-threatening or irreversibly debilitating diseases or conditions. The goal of the Breakthrough Devices Program is to provide patients and health care providers with timely access to these medical devices by speeding up their development, assessment, and review while preserving the statutory standards consistent with the Agency’s mission to protect and promote public health.

The Optimizer Smart Mini delivers CCM therapy which consists of precisely timed electrical pulses sent to the heart. These signals are designed to improve the heart’s ability to function properly, allowing more oxygen-rich blood to be pushed out through the body.

About Impulse Dynamics

Impulse Dynamics, based in Marlton, NJ, is dedicated to helping healthcare providers enhance the lives of people with heart failure by transforming how the condition is treated. The company has pioneered CCM® therapy, which is delivered by the company’s Optimizer® Smart Mini, an FDA-approved treatment verified to improve the quality of life for certain heart failure patients. CCM therapy is a safe, effective, and minimally invasive treatment option for many heart failure patients who otherwise have few effective options available to them. To learn more, visit www.ImpulseDynamics.com, or follow the company on LinkedInTwitter, and Facebook.

Forward-looking Statements

This press release contains forward-looking statements. All statements other than statements of historical facts contained in this press release are forward-looking statements. In some cases, you can identify forward-looking statements by terms such as ‘‘may,’’ ‘‘will,’’ ‘‘should,’’ ‘‘expect,’’ ‘‘plan,’’ ‘‘anticipate,’’ ‘‘could,’’ ‘‘intend,’’ ‘‘target,’’ ‘‘project,’’ ‘‘contemplate,’’ ‘‘believe,’’ ‘‘estimate,’’ ‘‘predict,’’ ‘‘potential’’ or ‘‘continue’’ or the negative of these terms or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements include, but are not limited to, statements concerning: potential benefits of CCM therapy and the ability for CCM therapy and our products to fill a significant unmet medical need for patients with heart failure; and the short-term and long-term benefits of the Optimizer Smart Mini and CCM therapy in patients with heart failure, as well as to the physicians treating those patients. These forward-looking statements are based on management’s current expectations and involve known and unknown risks and uncertainties that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Other important factors that could cause actual results, performance or achievements to differ materially from those contemplated in this press release include, without limitation: the Company’s future research and development costs, capital requirements and the Company’s needs for additional financing; commercial success and market acceptance of CCM therapy; the Company’s ability to achieve and maintain adequate levels of coverage or reimbursement for Optimizer Smart and Optimizer Smart Mini systems or any future products the Company may seek to commercialize; competitive companies and technologies in the industry; the Company’s ability to expand its indications and develop and commercialize additional products and enhancements to its current products; the Company’s business model and strategic plans for its products, technologies and business, including its implementation thereof; the Company’s ability to expand, manage and maintain its direct sales and marketing organization; the Company’s ability to commercialize or obtain regulatory approvals for CCM therapy and its products, or the effect of delays in commercializing or obtaining regulatory approvals; FDA or other U.S. or foreign regulatory actions affecting us or the healthcare industry generally, including healthcare reform measures in the United States and international markets; the timing or likelihood of regulatory filings and approvals; and the Company’s ability to establish and maintain intellectual property protection for CCM therapy and products or avoid claims of infringement. The Company does not undertake any obligation to update forward-looking statements and expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein. These forward-looking statements should not be relied upon as representing the Company’s views as of any date subsequent to the date of this press release.

Rex Richmond, Director (Media Relations)
Impulse Dynamics
856-642-9933
rrichmond@impulsedynamics.com

Harriss Currie, CFO (Investor Relations)
Impulse Dynamics
856-642-9933
hcurrie@impulsedynamics.com

Ian Segal, Manager (Public Relations)
Impulse Dynamics
856-642-9933
isegal@impulsedynamics.com

 

DAVOS ALZHEIMER’S COLLABORATIVE ANNOUNCES PARTNERSHIP WITH AGA KHAN UNIVERSITY TO LAUNCH FIRST ALZHEIMER’S RESEARCH INITIATIVE IN EAST AFRICA

Partnership Addresses the Growing Alzheimer’s Epidemic in Africa

GENEVA, SWITZERLAND, May 23, 2022 (GLOBE NEWSWIRE) —

  • Research Will Produce Digital Cognitive Assessments and Collect Blood Samples for Gene Sequencing Models
  • Clinical Trial Will Conduct Late-Stage Potential Treatment for Alzheimer’s
  • Builds on AKU’s Brain and Mind Institute to Develop Integrated Brain Health Frameworks

The Davos Alzheimer’s Collaborative (DAC), the organization leading an unprecedented global response to Alzheimer’s disease, today announced a partnership with the Brain & Mind Institute at Aga Khan University (AKU) in Kenya, East Africa to launch a two-part research program for Alzheimer’s: a cohort research study, and a clinical trial. Both will address the longstanding lack of diversity in Alzheimer’s research, aim to improve care, and increase access to future innovative treatments throughout Africa.

To date, nearly all studies of Alzheimer’s disease have been conducted on white populations of Western European origin, meaning that 90 percent of the world’s population has been left out.[1] The Davos Alzheimer’s Collaborative is responding to this lack of diversity by building a cohort of one million people, to date, 30 cohorts from 23 countries within North America, South America, Europe, Asia, and with this new partnership with the Brain & Mind Institute (BMI), AKU, Africa.

The partnership with the BMI/AKU is a trailblazing collaboration to fundamentally rethink Alzheimer’s data collection and analysis. Because the research will be open source, it will help scientists and researchers worldwide gain a better understanding of Alzheimer’s in vulnerable and underserved populations; which in turn, can accelerate the development of new treatments reflecting a precision medicine approach.

“To make progress on Alzheimer’s Disease, it is essential that research include all races and ethnicities, especially diverse populations who have been left out of previous research efforts,” said George Vradenburg, Founding Chairman of the Board, Davos Alzheimer’s Collaborative, and Convener, The Global CEO Initiative on Alzheimer’s Disease. This partnership with the Brain and Mind Institute/Aga Khan University will build knowledge across racial, ethnic, gender, and national boundaries which will lay the foundation for new breakthroughs.”

DAC and BMI will use local networks and on-the-ground healthcare providers to collect blood and conduct digital cognitive assessments, which are critical to identifying biomarkers that may indicate the presence of Alzheimer’s disease.

“We are excited to partner on this cutting-edge study to broaden our understanding of Alzheimer’s disease in Sub-Saharan Africa,” said Zul Merali, Founding Director of the Brain and Mind Institute, AKU. “This work comes at a critical time as the entire continent of Africa is grappling with issues of healthy aging and ill health, particularly pertaining to dementia and Alzheimer’s disease.”

DAC is transforming research in Alzheimer’s, working with researchers to make sure they have tools and technology to gather data, then pooling this information so the global scientific community can understand the heterogeneity of Alzheimer’s disease. The DAC/AKU partnership will play a key role in shaping a future of accessible, globally competent Alzheimer’s treatment.

 About the Davos Alzheimer’s Collaborative

Launched at the World Economic Forum’s 2021 meeting on The Davos Agenda, The Davos Alzheimer’s Collaborative is a multi-stakeholder partnership committed to aligning stakeholders with a new vision for our collective global response against the challenges Alzheimer’s presents to patients, caregivers and healthcare infrastructures. Convened by The World Economic Forum and The Global CEO Initiative on Alzheimer’s Disease (CEOi) and fueled by a mission of service to the estimated 150 million families and half a billion people inevitably impacted by this disease by 2050, DAC is a collaborative for the benefit of all people, in all places.

About the Brain and Mind Institute, AKU

The Brain and Mind Institute (BMI) at the Aga Khan University, operates in East Africa and Central/South Asia.  BMI’s ethos is to span from neuron to the neighborhood, and across multi-country campuses.  The operational model is to empower and strengthen neuroscience and mental health research and interventions through capacity building and partnerships; connecting the rich tapestry of academics, research entities, stakeholders, and communities of lived experience.  BMI facilitates interdisciplinary research, education and innovation in mental health and neurosciences. Through transdisciplinary research approaches, BMI aims to impact the lives of people who are affected by debilitating neurological and mental health problems. Whether it is uncovering the causes of illness or advancing breakthrough research into treatments or interventions, BMI’s approach is always mindful of the local needs of the people and communities at risk.


[1] https://www.davosalzheimerscollaborative.org/cohorts

Susan Oliver
Davos Alzheimer's Collaborative
+17032164078
soliver@davosalzheimerscollaborative.org

RobotPlusPlus, a Leader in Aerial Work Robots, Raises US$15M in Series B to Accelerate R&D and Expand Global Presence

BEIJING, May 23, 2022 /PRNewswire/ — RobotPlusPlus, a leader in aerial work robots, today announced its Series B funding round of US$15 million, bringing it to approximately US$35 million in total investment since its founding in 2017. This latest funding was led by Meituan, China’s leading tech and online retail company, and Fosun, a global innovation-driven consumer group.

Ship hull hydroblasting robot | Image credit: RobotPlusPlusRobotPlusPlus plans to use the new capital to accelerate its R&D timeline and expand its global presence. New robotic offerings will be released for cargo hold cleaning, tank painting, and facade cleaning, in addition to upgrading current products by integrating more autonomous technologies.

“Our latest round of funding contributes to the positive momentum we have been building over the past year. With a growing market share across our key territories, we look to continue to deliver more transformational results to our current and future clients,” said RobotPlusPlus founder and CEO Hua-yang Xu.

A storage tank hydroblasting robot | Image credit: RobotPlusPlusWith a mission to “empower humans with robots,” RobotPlusPlus has a portfolio of robotic solutions for crucial industries such as maritime, ship repair, petrochemicals, and power generation. The Company focuses on addressing the need to improve aerial work safety for operators while improving the efficiency of Inspection, Maintenance, and Repair (IMR) solutions and lowering operating costs for asset owners.

This has led RobotPlusPlus to be a market leader in magnetic crawler robots, with hundreds of robots already sold to clients worldwide. With its large team of skilled engineers and operators in place, RobotPlusPlus also provides Robot as a Service(RaaS) services to clients, enabling them not only to offer timely and cost-effective services but also to gain insights into industrial application scenarios.

Boiler inspection robot | Image credit: RobotPlusPlus“While we’ve previously focused on the Chinese market, 2021 has brought us more success outside China. We’re looking forward to making our solutions available to a broader audience and cementing our position as a key player globally,” stated Andy Lu, partner & SVP of RobotPlusPlus.

An example of this ambition is an upcoming office opening in Singapore to expand the Company’s ability to serve the Asian and Middle Eastern markets.

“An aging workforce, rising labor costs, frequent aerial work-related accidents, and the COVID-19 pandemic have had an accelerative effect on the aerial work robotics sector,” commented Pu Xiao, investment manager at Fosun. “RobotPlusPlus’ mission is to empower humans with robots while helping increase operational safety and productivity. We’re excited to support RobotPlusPlus in leveraging AI and RaaS to optimize aerial work environments and enable robotic applications.”

About RobotPlusPlus: 

Headquartered in Beijing, RobotPlusPlus is a technology company that builds aerial work robots. It provides cost-effective and environmentally friendly robotic solutions while guaranteeing a safer workplace.

RobotPlusPlus Press Contact:
Vivien Hao
vivien.hao@robotplusplus.cn

Related links
http://en.robotplusplus.com/

Photo – https://mma.prnewswire.com/media/1823346/image_1.jpg
Photo – https://mma.prnewswire.com/media/1823347/image_2.jpg
Photo – https://mma.prnewswire.com/media/1823348/image_3.jpg

DAVOS ALZHEIMER’S COLLABORATIVE ANNOUNCES EARLY DETECTION INNOVATION GRANTS

$4.5 Million in Grant Funding Expands New Alzheimer’s Early Detection and Healthcare System Preparedness Efforts

GENEVA, SWITZERLAND, May 23, 2022 (GLOBE NEWSWIRE) — The Davos Alzheimer’s Collaborative (DAC)the organization leading an unprecedented global response to Alzheimer’s disease, today announced the recipients of a grant program aiming for early detection of cognitive symptoms. The early detection grants total $4.5 Million from 8 countries across North America, Europe, Asia, and Africa.

The grants are an initiative of the DAC Healthcare System Preparedness Project, which aims to advance how healthcare systems worldwide detect, diagnose, treat, and care for people with or at risk for Alzheimer’s.

Grantees are located throughout the US, Brunei, Kenya, Germany, Japan, Canada, Cuba, and Armenia. Several grants will focus on expanding cognition screening and training for primary care providers. Others are harnessing innovative technologies to utilize optometrists and pharmacists. This will expand the pool of frontline workers available to screen for early detection, and reduce the unnecessary use of  specialist care. Another deploys a mobile clinic to offer direct clinical support or equip digital tablets to volunteer workers to rapidly improve detection  rates.

According to George Vradenburg, Founding Chairman of the Board, Davos Alzheimer’s Collaborative, “Each grant will bring unique and measurable benefits to its local health system and community and, through DAC’s global learning network, will also spread their learnings broadly around the world. Finding new and innovative ways to advance early detection is paramount to improving healthcare systems’ abilities to provide better care today, and to prepare for the future availability of treatments.”

The grant application process was extensive, with DAC receiving 76 responses from 21 countries in two months. A diverse panel of experts, including a family member of an Alzheimer’s patient living with the disease, served as an independent review committee for these grants:

  • Tarun Dua (Global) – World Health Organization
  • Wendy Weidner (Global) – Alzheimer’s Disease International
  • Ricardo Allegri (Argentina) – University of Buenos Aires & World Dementia Council
  • Chirine Chehab (Lebanon) – American University Hospital of Beirut
  • Lori Frank (United States) – RAND Corporation & New York Academy of Medicines
  • Ryoji Noritake (Japan) – Health and Global Policy Institute
  • Terry Fulmer (United States) – John A. Hartford Foundation
  • Chandresh Harjivan (Canada) – Family member of an Alzheimer’s patient

“Early detection of cognitive decline is critical for patients and families and I am excited to see the Davos Alzheimer’s Collaborative tackling this challenge with their Health System Preparedness Initiative,” says Chandresh Harjivan, a family member of an Alzheimer’s patient. “I was honored to be asked to be part of such an esteemed review committee and am very happy that families living with the disease were part of the evaluation process.”

A summary of each grant can be found below. 

About the Davos Alzheimer’s Collaborative

Launched at the World Economic Forum’s 2021 meeting on The Davos Agenda, The Davos Alzheimer’s Collaborative is a multi-stakeholder partnership committed to aligning stakeholders with a new vision for our collective global response against the challenges Alzheimer’s presents to patients, caregivers and healthcare infrastructures. Convened by The World Economic Forum and The Global CEO Initiative on Alzheimer’s Disease (CEOi) and fueled by a mission of service to the estimated 150 million families and half a billion people inevitably impacted by this disease by 2050, DAC is a collaborative for the benefit of all people, in all places.

About DAC’s Healthcare System Preparedness Project

DAC’s Healthcare System Preparedness Project (DAC-SP) is funding innovative approaches that measurably increase rates of cognitive screening, early detection and accurate diagnosis of Alzheimer’s through pilot projects and early detection grants. The pilot projects are: AdventHealth Central Florida, FL, USA; Municipality of Volta Redonda, State of Rio de Janeiro, Brazil; Alzheimer Scotland; University of the West Indies (UWI), Caribbean Institute for Health Research, Jamaica; Kobe University, Japan; INGER/National Institute of Geriatrics, Mexico; and, Indiana University School of Medicine/Indiana University Health, IN, USA. These initiatives are incorporated into DAC Learning Labs, a network of governments and public health and healthcare system leaders, to share best practices that can be scaled globally.

***PLEASE NOTE: Click here to view a recorded discussion with some of the grant recipients, in which over 500 global leaders from 53 countries tuned in to learn about early detection. Click here to be kept informed about updated information regarding the DAC initiative.

Davos Alzheimer’s Collaborative Early Detection Grants

Toronto Memory Program and RetiSpec (Canada)

This project implements the world’s first screening model that leverages collaboration between optometry and a local Alzheimer Society chapter to enable accessible identification of individuals at risk for Alzheimer’s disease and referral to a qualified clinician, facilitating a faster diagnosis. The two community-based entry points include: (1) optometry clinics, where individuals can receive a non-invasive RetiSpec retinal scan for early detection of Alzheimer’s disease; and (2) the Alzheimer Society of Toronto, where individuals can undergo cognitive assessment.

Ludwig-Maximillans University (Germany)       

Partners with two Universities, a health and social care charity, and three industry partners to conduct three screening types on seniors in Germany. This study will identify the best screening method by offering digital cognitive assessments, SCD questionnaire screening, and blood AD biomarkers testing to different groups. This study will also generate a patient registry to enroll patients in the global cohort and clinical trials workstreams, establish a fluid biobank, and train Artificial Intelligence diagnostic systems to better analyze speech patterns.

University of Havana (Cuba)

Provides a two-month training to primary care providers to integrate tablet based cognitive assessments Brain Health Assessment (BHA). The care provider will be assisted by informants, meaning a family-member or other person close to the patient, to help primary care providers determine if a dementia diagnosis is warranted.

Avant Institute (US – Multiple States)

This project implements Cognivue Clarity, a self-administered 10-minute cognitive performance screening tool, to increase access to digital cognitive screening assessments in 20-30 Community Pharmacy Enhanced Services Network (CPESN) pharmacy sites across rural, urban, and underserved communities throughout the United States. This project provides training and onboarding for pharmacies to use Cognivue to screen patients and evaluate the results to make further recommendations and referrals.

Africa Mental Health Research and Training Foundation (Kenya)

This project redeploys existing volunteer staff in the Strengthening Responses to Dementia in Developing Countries (STRiDE) project and trains community health workers to screen 2,400 people aged 60 and above. Workers are equipped with tablets to conduct the screening Instrument for Dementia (CSI-D) cognitive assessment and informant interview, word list recall task, and Euro-Dementia scale. Ultimately, results will inform health system policy and practices in Kenya. 

Alzheimer’s Care Armenia (Armenia)

This cognitive screening education programs utilizes a van that has been outfitted as a multidisciplinary mobile clinic to offer educational programs and work with local clinical staff to screen for cognitive issues using the Montreal Cognitive Assessment (MOCA). The program provides citizens who test positive for cognitive decline with healthcare resources and offers workshops to caregivers on providing support. 

Advocate Aurora Health (US- Illinois)

This project aims to educate primary care providers on the importance of early cognitive screening and provide them with EPIC electronic health record-based digital testing tools to manage their patients efficiently. Clinicians get access to continuing education programming, eConsult support services, and participate in a monthly Project ECHO-type case conference to discuss topics on dementia.

Kobe City Pharmaceutical Association (Japan)   

This project evaluates the value of pharmacy-based digital cognitive tests. It combines the cognitive test with a regular healthcare consultation to increase regular cognitive testing, the rate of early detection of cognitive decline, and timely and accurate diagnosis of dementia in local community-based healthcare system.

University of Washington (US- Washington)     

This project expands the pilot site success of the Gerontological Society of America (GSA) Kickstart, Assess, Evaluate and Refer (KAER Toolkit, 2020 Edition) into a fully operational Cognition in Primary Care (CPC) protocol in seven new primary care clinics across the University of Washington. The CPC model includes provider education training and incorporates two validated tests, the Montreal Cognitive Assessment (MoCa) and the Ascertain Dementia 8-Item Informant Questionnaire (AD8), and a structured Cognitive Checklist. This model checks for comorbidities of dementia and provides guidance on follow-up counseling and referrals to community resources. 

Demensia (Brunei)

This project will perform a pilot test of community screening and information in Senior Citizen Activity Centers, followed by a focus group discussion to select an initial paper-based cognitive assessment. The project will systematically involve communities at grassroots levels – senior citizen activity centres, engagement of village heads and community centres, targeting older people and those with dementia risk factors. Community links formed by the association are available for multisectoral support with this initiative. Other project activities also include training of field workers regarding community screening and cognitive assessment and training workshops for primary care (followed by relevant specialties).

American Academy of Physician Associates and Cleveland Clinic (US – Ohio)

Through partnership with The American Academy of Physician Assistants (AAPA), the Physician Associate (PA) Foundation, and Cleveland Clinic, this project develops cognitive assessment toolkit for non-specialist medical practitioners to be trained in administering screenings, interpreting results, communicating those results and offering additional provider and patient resources. The pilot implementation will be followed by outcomes reporting and dissemination of the toolkit to the network of PA schools and all Cleveland Clinic locations.

Institute for Healthcare Improvement (IHI) (US – Massachusetts)

This project uses a systems redesign approach, working with approximately eight teams across a range of settings on testing and measuring the results of intervention strategies that increase assessment rates. IHI will build and operate a learning community to encourage peer learning among participating teams, provide guidance, and teach scientific improvement methods to facilitate the teams’ testing. Project outputs include a prototype set of interventions, implementation guidance, and an associated measurement set that will be ready to share and scale more widely.

Susan Oliver
Davos Alzheimer's Collaborative
+17032164078
soliver@davosalzheimerscollaborative.org